心臓病用幹細胞市場(アプリケーション:心不全、心筋梗塞、重症四肢虚血、その他;Source:自己由来と同種由来)-世界の産業分析、サイズ、シェア、成長、トレンド、予測、2023-2031年Cardiology Stem Cells Market (Application: Heart Failure, Myocardial Infarction, Critical Limb Ischemia, and Others; Source: Autologous and Allogenic) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 心臓病用幹細胞市場 - レポートの範囲 TMRの調査レポート「世界の心臓病用幹細胞市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や... もっと見る
サマリー心臓病用幹細胞市場 - レポートの範囲TMRの調査レポート「世界の心臓病用幹細胞市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの期間における世界の心臓病用幹細胞市場の収益を提供します。また、2023年から2031年までの世界の心臓病用幹細胞市場の複合年間成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行いました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、心臓病用幹細胞市場を把握しました。 二次調査には、インターネットソース、政府機関、ウェブサイト、業界団体の統計データも含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の心臓病用幹細胞市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の心臓病用幹細胞市場における競争力学の変化に光を投げかけています。これらは、既存の市場関係者だけでなく、世界の心臓病用幹細胞市場への参入に関心を持つ事業者にとっても貴重なツールとなります。 本レポートは、世界の心臓病用幹細胞市場の競争環境について掘り下げています。世界の心臓病用幹細胞市場で活動する主要企業が特定され、これらの各企業は様々な属性でプロファイルされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の心臓病用幹細胞市場のプレーヤーの属性です。 世界の心臓病用幹細胞市場レポートで回答された主要な質問 - 予測期間中にすべての地域で発生した心臓病学的幹細胞の売上高/収益はどのくらいですか? - 世界の心臓病用幹細胞市場におけるビジネスチャンスは何か? - 市場における主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大するのはどの地域市場か? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか? - 世界市場で事業展開している各社の市場ポジションは? 心臓病用幹細胞市場 - 研究目的と研究アプローチ 世界の心臓病用幹細胞市場に関する包括的なレポートは、概要から始まり、研究の範囲と目的について説明します。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。 読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。 本レポートでは、世界の心臓病用幹細胞市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は、世界の心臓病用幹細胞市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Cardiology Stem Cells Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Bn) 5. Key Insights 5.1. Key Mergers & Acquisitions 5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact) 5.3. Pipeline Analysis 5.4. Disease Prevalence & Incidence Rate globally with key countries 6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Type of Cell, 2017-2031 6.3.1. Embryonic Stem Cells 6.3.2. Adult Stem Cells 6.3.3. Induced Pluripotent Stem Cells 6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 6.4. Market Attractiveness Analysis, by Type of Cell 7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Application, 2017-2031 7.3.1. Heart Failure 7.3.2. Myocardial Infarction 7.3.3. Critical Limb Ischemia 7.3.4. Others 7.4. Market Attractiveness Analysis, by Application 8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Source, 2017-2031 8.3.1. Autologous 8.3.2. Allogenic 8.4. Market Attractiveness Analysis, by Source 9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by End-user, 2017-2031 9.3.1. Pharmaceutical & Biotechnology Companies 9.3.2. Hospitals & Cell Banks 9.3.3. Academic & Research Institutes 9.4. Market Attractiveness Analysis, by End-user 10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness Analysis, by Region 11. North America Cardiology Stem Cells Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Type of Cell, 2017-2031 11.2.1. Embryonic Stem Cells 11.2.2. Adult Stem Cells 11.2.3. Induced Pluripotent Stem Cells 11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 11.3. Market Value Forecast, by Application, 2017-2031 11.3.1. Heart Failure 11.3.2. Myocardial Infarction 11.3.3. Critical Limb Ischemia 11.3.4. Others 11.4. Market Value Forecast, by Source, 2017-2031 11.4.1. Autologous 11.4.2. Allogenic 11.5. Market Value Forecast, by End-user, 2017-2031 11.5.1. Pharmaceutical & Biotechnology Companies 11.5.2. Hospitals & Cell Banks 11.5.3. Academic & Research Institutes 11.6. Market Value Forecast, by Country, 2017-2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Type of Cell 11.7.2. By Application 11.7.3. By Source 11.7.4. By End-user 11.7.5. By Country 12. Europe Cardiology Stem Cells Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Type of Cell, 2017-2031 12.2.1. Embryonic Stem Cells 12.2.2. Adult Stem Cells 12.2.3. Induced Pluripotent Stem Cells 12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 12.3. Market Value Forecast, by Application, 2017-2031 12.3.1. Heart Failure 12.3.2. Myocardial Infarction 12.3.3. Critical Limb Ischemia 12.3.4. Others 12.4. Market Value Forecast, by Source, 2017-2031 12.4.1. Autologous 12.4.2. Allogenic 12.5. Market Value Forecast, by End-user, 2017-2031 12.5.1. Pharmaceutical & Biotechnology Companies 12.5.2. Hospitals & Cell Banks 12.5.3. Academic & Research Institutes 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Type of Cell 12.7.2. By Application 12.7.3. By Source 12.7.4. By End-user 12.7.5. By Country/Sub-region 13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Type of Cell, 2017-2031 13.2.1. Embryonic Stem Cells 13.2.2. Adult Stem Cells 13.2.3. Induced Pluripotent Stem Cells 13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 13.3. Market Value Forecast, by Application, 2017-2031 13.3.1. Heart Failure 13.3.2. Myocardial Infarction 13.3.3. Critical Limb Ischemia 13.3.4. Others 13.4. Market Value Forecast, by Source, 2017-2031 13.4.1. Autologous 13.4.2. Allogenic 13.5. Market Value Forecast, by End-user, 2017-2031 13.5.1. Pharmaceutical & Biotechnology Companies 13.5.2. Hospitals & Cell Banks 13.5.3. Academic & Research Institutes 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031 13.6.1. Japan 13.6.2. China 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Type of Cell 13.7.2. By Application 13.7.3. By Source 13.7.4. By End-user 13.7.5. By Country/Sub-region 14. Latin America Cardiology Stem Cells Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Type of Cell, 2017-2031 14.2.1. Embryonic Stem Cells 14.2.2. Adult Stem Cells 14.2.3. Induced Pluripotent Stem Cells 14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 14.3. Market Value Forecast, by Application, 2017-2031 14.3.1. Heart Failure 14.3.2. Myocardial Infarction 14.3.3. Critical Limb Ischemia 14.3.4. Others 14.4. Market Value Forecast, by Source, 2017-2031 14.4.1. Autologous 14.4.2. Allogenic 14.5. Market Value Forecast, by End-user, 2017-2031 14.5.1. Pharmaceutical & Biotechnology Companies 14.5.2. Hospitals & Cell Banks 14.5.3. Academic & Research Institutes 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Type of Cell 14.7.2. By Application 14.7.3. By Source 14.7.4. By End-user 14.7.5. By Country/Sub-region 15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Type of Cell, 2017-2031 15.2.1. Embryonic Stem Cells 15.2.2. Adult Stem Cells 15.2.3. Induced Pluripotent Stem Cells 15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 15.3. Market Value Forecast, by Application, 2017-2031 15.3.1. Heart Failure 15.3.2. Myocardial Infarction 15.3.3. Critical Limb Ischemia 15.3.4. Others 15.4. Market Value Forecast, by Source, 2017-2031 15.4.1. Autologous 15.4.2. Allogenic 15.5. Market Value Forecast, by End-user, 2017-2031 15.5.1. Pharmaceutical & Biotechnology Companies 15.5.2. Hospitals & Cell Banks 15.5.3. Academic & Research Institutes 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Type of Cell 15.7.2. By Application 15.7.3. By Source 15.7.4. By End-user 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (By Tier and Size of companies) 16.2. Market Share Analysis By Company (2022) 16.3. Company Profiles 16.3.1. Astellas Pharma, Inc. 16.3.1.1. Company Overview 16.3.1.2. Product Portfolio 16.3.1.3. SWOT Analysis 16.3.1.4. Strategic Overview 16.3.2. STEMCELL Technologies 16.3.2.1. Company Overview 16.3.2.2. Product Portfolio 16.3.2.3. SWOT Analysis 16.3.2.4. Strategic Overview 16.3.3. Cellular Engineering Technologies 16.3.3.1. Company Overview 16.3.3.2. Product Portfolio 16.3.3.3. SWOT Analysis 16.3.3.4. Strategic Overview 16.3.4. BioTimes, Inc. 16.3.4.1. Company Overview 16.3.4.2. Product Portfolio 16.3.4.3. SWOT Analysis 16.3.4.4. Strategic Overview 16.3.5. Takara Bio, Inc. 16.3.5.1. Company Overview 16.3.5.2. Product Portfolio 16.3.5.3. SWOT Analysis 16.3.5.4. Strategic Overview 16.3.6. U.S. Stem Cell, Inc. 16.3.6.1. Company Overview 16.3.6.2. Product Portfolio 16.3.6.3. SWOT Analysis 16.3.6.4. Strategic Overview 16.3.7. BrainStorm Cell Limited 16.3.7.1. Company Overview 16.3.7.2. Product Portfolio 16.3.7.3. SWOT Analysis 16.3.7.4. Strategic Overview 16.3.8. Cytori Therapeutics, Inc. 16.3.8.1. Company Overview 16.3.8.2. Product Portfolio 16.3.8.3. SWOT Analysis 16.3.8.4. Strategic Overview 16.3.9. Bio Cardia, Inc. 16.3.9.1. Company Overview 16.3.9.2. Product Portfolio 16.3.9.3. SWOT Analysis 16.3.9.4. Strategic Overview 図表リストList of TablesTable 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031 Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031 Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031 Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031 Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031 Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031 Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
SummaryCardiology Stem Cells Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Cardiology Stem Cells Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031 4.4.1. Market Revenue Projections (US$ Bn) 5. Key Insights 5.1. Key Mergers & Acquisitions 5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact) 5.3. Pipeline Analysis 5.4. Disease Prevalence & Incidence Rate globally with key countries 6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Type of Cell, 2017-2031 6.3.1. Embryonic Stem Cells 6.3.2. Adult Stem Cells 6.3.3. Induced Pluripotent Stem Cells 6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 6.4. Market Attractiveness Analysis, by Type of Cell 7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Application, 2017-2031 7.3.1. Heart Failure 7.3.2. Myocardial Infarction 7.3.3. Critical Limb Ischemia 7.3.4. Others 7.4. Market Attractiveness Analysis, by Application 8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Source, 2017-2031 8.3.1. Autologous 8.3.2. Allogenic 8.4. Market Attractiveness Analysis, by Source 9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by End-user, 2017-2031 9.3.1. Pharmaceutical & Biotechnology Companies 9.3.2. Hospitals & Cell Banks 9.3.3. Academic & Research Institutes 9.4. Market Attractiveness Analysis, by End-user 10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness Analysis, by Region 11. North America Cardiology Stem Cells Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Type of Cell, 2017-2031 11.2.1. Embryonic Stem Cells 11.2.2. Adult Stem Cells 11.2.3. Induced Pluripotent Stem Cells 11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 11.3. Market Value Forecast, by Application, 2017-2031 11.3.1. Heart Failure 11.3.2. Myocardial Infarction 11.3.3. Critical Limb Ischemia 11.3.4. Others 11.4. Market Value Forecast, by Source, 2017-2031 11.4.1. Autologous 11.4.2. Allogenic 11.5. Market Value Forecast, by End-user, 2017-2031 11.5.1. Pharmaceutical & Biotechnology Companies 11.5.2. Hospitals & Cell Banks 11.5.3. Academic & Research Institutes 11.6. Market Value Forecast, by Country, 2017-2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Type of Cell 11.7.2. By Application 11.7.3. By Source 11.7.4. By End-user 11.7.5. By Country 12. Europe Cardiology Stem Cells Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Type of Cell, 2017-2031 12.2.1. Embryonic Stem Cells 12.2.2. Adult Stem Cells 12.2.3. Induced Pluripotent Stem Cells 12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 12.3. Market Value Forecast, by Application, 2017-2031 12.3.1. Heart Failure 12.3.2. Myocardial Infarction 12.3.3. Critical Limb Ischemia 12.3.4. Others 12.4. Market Value Forecast, by Source, 2017-2031 12.4.1. Autologous 12.4.2. Allogenic 12.5. Market Value Forecast, by End-user, 2017-2031 12.5.1. Pharmaceutical & Biotechnology Companies 12.5.2. Hospitals & Cell Banks 12.5.3. Academic & Research Institutes 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Italy 12.6.5. Spain 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. By Type of Cell 12.7.2. By Application 12.7.3. By Source 12.7.4. By End-user 12.7.5. By Country/Sub-region 13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Type of Cell, 2017-2031 13.2.1. Embryonic Stem Cells 13.2.2. Adult Stem Cells 13.2.3. Induced Pluripotent Stem Cells 13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 13.3. Market Value Forecast, by Application, 2017-2031 13.3.1. Heart Failure 13.3.2. Myocardial Infarction 13.3.3. Critical Limb Ischemia 13.3.4. Others 13.4. Market Value Forecast, by Source, 2017-2031 13.4.1. Autologous 13.4.2. Allogenic 13.5. Market Value Forecast, by End-user, 2017-2031 13.5.1. Pharmaceutical & Biotechnology Companies 13.5.2. Hospitals & Cell Banks 13.5.3. Academic & Research Institutes 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031 13.6.1. Japan 13.6.2. China 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. By Type of Cell 13.7.2. By Application 13.7.3. By Source 13.7.4. By End-user 13.7.5. By Country/Sub-region 14. Latin America Cardiology Stem Cells Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Type of Cell, 2017-2031 14.2.1. Embryonic Stem Cells 14.2.2. Adult Stem Cells 14.2.3. Induced Pluripotent Stem Cells 14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 14.3. Market Value Forecast, by Application, 2017-2031 14.3.1. Heart Failure 14.3.2. Myocardial Infarction 14.3.3. Critical Limb Ischemia 14.3.4. Others 14.4. Market Value Forecast, by Source, 2017-2031 14.4.1. Autologous 14.4.2. Allogenic 14.5. Market Value Forecast, by End-user, 2017-2031 14.5.1. Pharmaceutical & Biotechnology Companies 14.5.2. Hospitals & Cell Banks 14.5.3. Academic & Research Institutes 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. By Type of Cell 14.7.2. By Application 14.7.3. By Source 14.7.4. By End-user 14.7.5. By Country/Sub-region 15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Type of Cell, 2017-2031 15.2.1. Embryonic Stem Cells 15.2.2. Adult Stem Cells 15.2.3. Induced Pluripotent Stem Cells 15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells 15.3. Market Value Forecast, by Application, 2017-2031 15.3.1. Heart Failure 15.3.2. Myocardial Infarction 15.3.3. Critical Limb Ischemia 15.3.4. Others 15.4. Market Value Forecast, by Source, 2017-2031 15.4.1. Autologous 15.4.2. Allogenic 15.5. Market Value Forecast, by End-user, 2017-2031 15.5.1. Pharmaceutical & Biotechnology Companies 15.5.2. Hospitals & Cell Banks 15.5.3. Academic & Research Institutes 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. By Type of Cell 15.7.2. By Application 15.7.3. By Source 15.7.4. By End-user 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (By Tier and Size of companies) 16.2. Market Share Analysis By Company (2022) 16.3. Company Profiles 16.3.1. Astellas Pharma, Inc. 16.3.1.1. Company Overview 16.3.1.2. Product Portfolio 16.3.1.3. SWOT Analysis 16.3.1.4. Strategic Overview 16.3.2. STEMCELL Technologies 16.3.2.1. Company Overview 16.3.2.2. Product Portfolio 16.3.2.3. SWOT Analysis 16.3.2.4. Strategic Overview 16.3.3. Cellular Engineering Technologies 16.3.3.1. Company Overview 16.3.3.2. Product Portfolio 16.3.3.3. SWOT Analysis 16.3.3.4. Strategic Overview 16.3.4. BioTimes, Inc. 16.3.4.1. Company Overview 16.3.4.2. Product Portfolio 16.3.4.3. SWOT Analysis 16.3.4.4. Strategic Overview 16.3.5. Takara Bio, Inc. 16.3.5.1. Company Overview 16.3.5.2. Product Portfolio 16.3.5.3. SWOT Analysis 16.3.5.4. Strategic Overview 16.3.6. U.S. Stem Cell, Inc. 16.3.6.1. Company Overview 16.3.6.2. Product Portfolio 16.3.6.3. SWOT Analysis 16.3.6.4. Strategic Overview 16.3.7. BrainStorm Cell Limited 16.3.7.1. Company Overview 16.3.7.2. Product Portfolio 16.3.7.3. SWOT Analysis 16.3.7.4. Strategic Overview 16.3.8. Cytori Therapeutics, Inc. 16.3.8.1. Company Overview 16.3.8.2. Product Portfolio 16.3.8.3. SWOT Analysis 16.3.8.4. Strategic Overview 16.3.9. Bio Cardia, Inc. 16.3.9.1. Company Overview 16.3.9.2. Product Portfolio 16.3.9.3. SWOT Analysis 16.3.9.4. Strategic Overview List of Tables/GraphsList of TablesTable 01: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 02: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 03: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 04: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 05: Global Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Region, 2017–2031 Table 06: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country, 2017–2031 Table 07: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 08: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 09: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 10: North America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 11: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-Region, 2017–2031 Table 12: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 13: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 14: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 15: Europe Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 16: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031 Table 17: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 18: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 19: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 20: Asia Pacific Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 21: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031 Table 22: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 23: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 24: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 25: Latin America Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031 Table 26: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031 Table 27: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Type of Cell, 2017‒2031 Table 28: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Application, 2017‒2031 Table 29: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by Source, 2017‒2031 Table 30: Middle East & Africa Cardiology Stem Cells Market Value (US$ Bn) Forecast, by End-user, 2017–2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポートTransparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(heart failure)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/09 10:27 143.78 円 159.73 円 191.51 円 |